echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and development daily newspaper for the first time in 15 years! Mercadon anti-infection new drug declared on the market in China

    Research and development daily newspaper for the first time in 15 years! Mercadon anti-infection new drug declared on the market in China

    • Last Update: 2021-01-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020.11.18 Research and Development NEWS: Clinical applications for CDK 4/6 inhibitors introduced by Sonic Pharmaceuticals for US$170 million were accepted; mid-term analysis of the NSCLC III study for Reilly Pearl Monotherapy NSCLC III reached the main endpoint of OS; Wee1 inhibitors from Yingpai Pharmaceuticals were admitted to clinical trials in the United States; new lysovirus therapy: intravenous injection exceeded the limits of the drug route! ...... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
    (click on the title, read the original) "Drug Research and Development" Runxin Bio 3rd Generation EGFR-TKI New Drug Key Registration Phase 3 Clinical Completion of the First Patient Administration Today, Runxin Bio announced that it has completed the first phase 3 clinical study of the new drug RX518 for the first line of treatment of non-small cell lung cancer in Shanghai Hospital.
    mid-term analysis of the phase III study of the treatment of rellijutin monotherapy reached the main end point of OS on the 17th, Baiji Shenzhou announced the progress of the disease after it was used to evaluate the treatment of reilly pearl single anti-dossin for platinum chemotherapy. In a pre-planned mid-term analysis of RATIONALE 303 clinical trials in patients with second- or third-line localized advanced or metastasis non-small cell lung cancer (NSCLC), the primary endpoint of total survival (OS) was achieved in patients intended to be treated.
    The weekly 2.0mg Somaglutide significantly reduces HbA1c in patients with type 2 diabetes on November 17th, Noel and Nord announced the main results of the SUSTAIN FORTE trial, which significantly reduced the glycoglobin (HbA1c) to reach the main endpoint of the trial compared to the weekly treatment of 1.0 mg Somalutide.
    The first one-year results of a phase 3 study of the biosynthetic drug SB11 SB11 to treat the age-related macular degeneration (nAMD) of newborn blood vessels have been published by Samsung Bioepis, which is comparable to reniocentesis.
    based on 52 weeks of data, SB11 is equivalent to the reference drug Reniju single resistance in terms of drug ability and pharmacogenetics, and that safety and immunogenicity are comparable to reference drugs.
    INOVIO today announced phase 2/3 phase 2 of the new crown vaccine trial, INOVIO announced that it has obtained FDA approval to proceed with the planned phase 2/3 phase of the phase 2/3 clinical trial of the new crown pneumonia vaccine INO-4800.
    the first in 15 years! Mercadon anti-infective new drugs declared on the market in China today, CDE recently announced that Mesadong antiviral drug letermovir submitted four new drug listing applications and received, including injections and tablets of two dosage forms.
    the drug, which was approved by the FDA in November 2017, is the first new drug approved in the United States in 15 years to treat CMV infection and prevent cytovirus (CMV) infections and related diseases.
    clinical application for CDK 4/6 inhibitors introduced by Syngenta Pharmaceuticals was accepted today, the latest CDE announcement, jointly declared by Syngenta Pharmaceuticals and G1 Therapeutics for a class 1 new drug injection trilaciclib clinical trial application was accepted.
    is a "first-in-class" CDK 4/6 inhibitor that has been awarded FDA priority review eligibility and breakthrough therapy.
    British Pharmaceuticals Wee1 inhibitors were approved for clinical trials in the United States today, British Pharmaceuticals announced that the company's self-developed Wee1 inhibitor IMP7068 was approved by the FDA Clinical Trials on October 29, 2020 local time in the United States, is about to launch its first clinical trial.
    Zee-Pharma Obeid magnesium tablets were approved for drug clinical trials on the 18th, Zee-Bio issued a notice that the company's magnesium obecholic acid tablets for the treatment of primary bile gallbladitis and non-alcoholic fatty hepatitis I/II, Phase III clinical trials were approved to carry out.
    Lu anti-pharmaceutical subsidiary by the hydrochloric acid bromoso injection drug registration certificate 18, Lu anti-pharmaceutical issued a notice that the holding subsidiary Shandong Lu anti-drug group Cyt Co., Ltd. recently received the State Drug Administration issued the hydrochloric acid bromoso injection "drug registration certificate."
    East Sunshine Pharmaceuticals imitation 4 categories of Tigrelo tablets were approved for production and as reviewed recently, Guangdong East Sunshine Pharmaceuticals to copy 4 categories of declared Tegrelo tablets were approved for production and as reviewed.
    the current East Sunshine drug in the trial of the new classification of products have 24 species, hydrochloric acid fingomod capsules, Enta carpon tablets, etc. have not yet been approved for the first imitation.
    2 more than 2 billion injections Colum, Howson's first review recently, Sichuan Colum Pharmaceuticals fat lactate amino acids (17) glucose (11%) injection, Jiangsu Haussen Pharmaceuticals injections of escapronics have been evaluated, are the first in China.
    Latest Research: New Lysovirus Therapy: Intravenously Break through the limits of the route of drugation! OncoMyx recently presented preclinical efficacy data for a multigene lysovirus therapy at the BITC 2020 conference: it was shown for the first time that the treatment significantly slowed the growth of multiple tumor types when administered intravenously or intra-tumor, 1 alone or in combination with immuno-checkpoint inhibitors, and was more effective in reducing tumors and prolonging animal life when used in combination with immuno-checkpoint inhibitors.
    hiv pre-exposure prevention effect increased by 66%! Cabotegravir was eligible for breakthrough therapy on July 17, viiV Healthcare announced that the FDA has awarded its long-acting integrated enzyme inhibitor Cabotegravir breakthrough therapy for pre-exposure HIV prevention (PrEP), the results of which were presented at the 23rd International AIDS Congress (AIDS 2020) in July this year.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.